Vastavam web: Russia has approved R-Pharm’s Coronavir treatment for outpatients with mild to moderate COVID-19 infections and the antiviral drug could be rolled out to pharmacies in the country as soon as next week, the company said on Friday. Coronavir’s approval as a prescription drug follows the green light for another Russian COVID-19 drug, Avifavir, in May. Both are based on favipiravir, which was developed in Japan and is widely used there as the basis for viral treatments.
R-Pharm said it received approval for Coronavir after Phase III clinical trials involving 168 patients with COVID-19. The drug was first approved for in-hospital use to treat COVID-19 in July, a government register showed. R-Pharm has started talks with pharmacies about orders, the company’s spokeswoman said, with Coronavir supplies expected to be rolled out in the near future, possibly as soon as next week. Coronavir is made at R-Pharm’s facility in Yaroslavl, about 300 km (186 miles) northeast of Moscow.